Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spago Nanomedical ABFRA:7UX -6.25%34 FCF Yield % is -27.61 as of Jul. 29, 2026. GuruFocus rates FRA:7UX with a GF Score™ of 34/100. The stock has 4 warning signs investors should review. Among 1,407 Biotechnology companies, Spago Nanomedical AB ranks worse than 71.64% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Spago Nanomedical AB FCF Yield % Related Terms
Spago Nanomedical AB FCF Yield % Historical Data
* Premium members only.
The historical data trend for Spago Nanomedical AB's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7UX vs VRTX, REGN, RVMD: FCF Yield % Comparison
For the Biotechnology subindustry, Spago Nanomedical AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spago Nanomedical AB FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Spago Nanomedical AB's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spago Nanomedical AB (FRA:7UX) has a FCF Yield % of -27.61 as of Jul. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Spago Nanomedical AB and its competitors. According to the industry distribution chart, Spago Nanomedical AB ranks #1008 out of 1407 companies in the Biotechnology industry, placing it in the top 71.6%.
Is Spago Nanomedical AB's FCF Yield % too high?
Spago Nanomedical AB's current FCF Yield % is -27.61. Based on the distribution chart, Spago Nanomedical AB ranks #1008 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Spago Nanomedical AB has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Spago Nanomedical AB ranks #1008 out of 1407 companies for FCF Yield %. This places Spago Nanomedical AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Spago Nanomedical AB and its competitors. Spago Nanomedical AB's current FCF Yield % is -27.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Spago Nanomedical AB (FRA:7UX) has a current FCF Yield % of -27.61. The current FCF Yield % is -27.61. Spago Nanomedical AB's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Spago Nanomedical AB (FRA:7UX), the current FCF Yield % is -27.61 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
34GF Score
Get the complete analysis for FRA:7UX
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7UX has been successfully added to your 
